Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.
نویسندگان
چکیده
Current therapy of primary systemic (AL) amyloidosis with oral melphalan and prednisone remains unsatisfactory, with a median survival of only 13 months. Between 1996 and 2003, 93 patients with biopsy-proven AL amyloidosis were enrolled in a prospective US national cooperative group trial. Treatment schema consisted of induction therapy with pulse dexamethasone (DEX), followed by maintenance therapy with DEX and alpha interferon. Hematologic complete remissions were observed in 24% and improvement in AL amyloidosis-related organ dysfunction occurred in 45% of patients evaluable for response. Median survival of the entire cohort is 31 months, with an estimated 2-year overall survival (OS) and event-free survival (EFS) of 60% and 52%, respectively. Presence of congestive heart failure and increased level of serum beta2 microglobulin (>/= 0.0035 g/L [3.5 mg/L]) were dominant predictors of adverse outcome. Estimated 2-year OS in patients who are eligible to receive transplants with this approach was 78%. These data demonstrate for the first time in the context of a US multicenter prospective clinical trial that front-line therapy with a DEX-based regimen in AL amyloidosis can lead to durable reversal of AL amyloidosis-related organ dysfunction and prolonged survival.
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/ alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group
Current therapy of primary systemic (AL) amyloidosis with oral melphalan and prednisone remains unsatisfactory, with a median survival of only 13 months. Between 1996 and 2003, 93 patients with biopsyproven AL amyloidosis were enrolled in a prospective US national cooperative group trial. Treatment schema consisted of induction therapy with pulse dexamethasone (DEX), followed by maintenance the...
متن کاملCounterpoint: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma.
Multiagent induction chemotherapy leads to high response rates in multiple myeloma. The phase III Southwest Oncology Group trial involving 525 patients established lenalidomide, bortezomib, and dexamethasone (RVD) as a preferred induction regimen; in this trial, RVD demonstrated an overall response rate of 81.5%, with 15.7% of responses complete responses (CR), and 27.8% very good partial respo...
متن کاملTreatment of Postoperative Shivering with Dexamethasone: A Prospective Randomized Clinical Trial
Background: Postoperative shivering is an important and troublesome condition during recovery from general anesthesia. Corticosteroids have been recommended to facilitate recovery and diminish shivering after cardiac surgery. Previous studies recommended 0.6 mg/kg dexamethasone for reducing postoperative shivering in patients undergoing cardiac surgery. Objective: To test this assertion, we...
متن کاملHigh-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
BACKGROUND High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation has been reported to provide higher response rates and better overall survival than standard chemotherapy in immunoglobulin-light-chain (AL) amyloidosis, but these two strategies have not been compared in a randomized study. METHODS We conducted a randomized trial comparing high-dose intravenous m...
متن کاملDexamethasone vs Hydrocortisone in Management of Exacerbated Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial
Background: Different types of corticosteroids with different characteristics, such as hydrocortisone and dexamethasone, have been used in treatment of exacerbated chronic obstructive pulmonary disease but drug of choice unclear. The main goal of present study was to compare the efficacy of hydrocortisone and dexamethasone on clinical symptoms, peak expiratory flow, oxidative stress factors and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Blood
دوره 104 12 شماره
صفحات -
تاریخ انتشار 2004